List of Genetic Analysis/Screening Companies in California - 89

Cells are the basic unit of life. They power everything we do, and unlocking their secrets is the key to advancing our knowledge of every facet of biology, from development to disease. Our single cell, spatial, and in situ tools enable researchers to answer pressing questions about cells and their functional contributions to oncology, immunology, neuroscience, and much more—as evidenced by more than 5,500 publications citing our technology. We are dedicated to building the best products, delivering the best customer experience, and creating the best team to fuel new scientific discovery, no matter how challenging. And we won’t stop until all of the cells’ secrets are revealed.

We’re leveraging advances in genetics and precision medicine to develop new therapeutics that target shared, underlying biology in rare and common diseases — bringing meaningful medicines from one to many. With expertise in genetics, drug discovery and data sciences, we seek to identify programs where both biological and technical risk can be minimized to streamline the drug development process and bring forward exceptionally potent and precisely targeted therapeutics for patients.

Aegea Biotechnologies, Inc. is a technology company that is developing a series of reagents, research kits and in-vitro diagnostic (IVD) products for molecular analysis based on novel, patented and proprietary nucleic acid chemistries and methodologies.

Agena Bioscience® empowers research laboratories worldwide to deliver scalable targeted genomic data. Our advanced platforms deliver timely molecular insights in the areas of mutation profiling, liquid biopsy, pharmacogenetics, and more. Agena offers the MassARRAY® System, an open platform that provides researchers with insights through a highly multiplexed solution. Headquartered in San Diego, with offices located around the world, Agena Bioscience fosters a highly collaborative culture for both our customers and employees, encouraging diversity, creativity, and most importantly, innovation.

Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing patients with early stage breast cancer and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient. MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings. Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of patients with breast cancer and their physicians every step of the way, from initial diagnosis to cancer-free. Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com. For view our social media policies, please visit https://agendia.com/legal-compliance/

Alcala Labs was founded by a partnership between a healthcare attorney specializing in the defense of individual and institutional healthcare providers and a physician with one of the largest pain management practices in Southern California. The lab grew out of frustration with existing laboratory providers and the conviction that Alcala Labs could do better. Smaller labs were not scientifically up to the task and, in many cases, were simply dishonest about the services they provided. Larger labs were either unresponsive or subcontracted critical complex lab services to unaccountable third-party labs . Alcala Labs was built to react quickly to the needs of physicians who need to understand drug use and efficacy in their practices. The Alcala difference is accessibility to its physician customers, responsiveness to their needs and inquiries, and customizable lab testing. If a physician has a medical-legal question that arises from testing, he can immediately reach the company's healthcare attorney President. If a physician requires insight into how a particular test affects the course of a patient's care, she can engage in a dialogue directly with the lab's Medical Director. If there are questions about science and the development of new tests, our highly credentialed scientific team can be reached directly. Widely in demand among a variety of specialties, Alcala Labs is of especial importance to drug rehabilitation, pain management, and psychiatry practices. We're able to add assays as illicit "designer" drugs begin to appear, and our new pharmacogenetic department gives physicians the power to anticipate the right drugs and dosages to best treat their patients. Located in San Diego, Alcala is a laboratory of national reach and reputation. It is among the fastest growing labs in the country, dedicated to state-of-the-art science and the highest quality service.

Alida Biosciences is an early-stage, VC backed startup in San Diego focused on developing novel genomic analysis tools. The company’s technology will advance the understanding of RNA biology and provide actionable information for improving human health.

Ambry Genetics is a company built by scientists, genetic counselors and physicians, dedicated to leading the clinical genomic diagnostic industry. Ambry boasts the largest genetic sequencing lab in the world; is CAP-accredited, CLIA-licensed and, as part of the Konica Minolta family, has access to the most complete suite of diagnostic technology in the world. Ambry Genetics'​ scope of clients includes some of the world's most respected academic institutions, pharmaceutical companies and leading treatment hospitals. Our experience, technology and dedication to science make us a trusted source for all clinical genetic testing, and an ideal partner for developing precision medicine solutions. Patients are at the core of everything we do, which is why Ambry partners with several non-profit organizations so that we can help both patients and clinicians alike find answers. Hiring Fraud Alert: Ambry/REALM IDx has received reports of employment scams in recent months that seek financial commitments, or requests personal information from job candidates. Unsuspecting job seekers have reported receiving unsolicited contacts by phone, email or text from individual(s) posing to be or represent Ambry/REALM IDx recruiter(s). If you've experienced either of these scenarios, please visit this page to learn more about hiring fraud: https://consumer.ftc.gov/articles/job-scams. Or visit https://realmidx.com/careers/recruitment-fraud-alert/ to learn more about our policy on recruitment fraud. You can confirm the legitimacy of a job posting by viewing our current open roles at https://realmidx.com/careers/.

At Ansa Biotechnologies, we’re developing a way to synthesize DNA that will accelerate innovation in medicine, agriculture, and industrial biotechnology. Our fast, clean, and accurate enzymatic DNA synthesis process can produce gene-length molecules directly, overcoming bottlenecks of traditional DNA synthesis methods. We envision a future where our technology empowers scientists to develop solutions for the world's biggest problems in health and sustainability. Note that Ansa does not conduct any employment discussions via LinkedIn. All official Ansa career openings are exclusively listed on our website careers page.

Arima-HiC is a proximity ligation method that captures the three-dimensional organizational structure of chromatin, where genomic sequences that are distal to each other in linear distance can be closer to each other in the 3D space. The high-resolution, genome-wide map of interacting genetic loci that is generated from Hi-C data can then be used across multiple genomic applications including identification of promoter-enhancer interactions for gene regulation studies and scaffolding contigs for genome assemblies to define chromosomes de novo.

Focusing on developing the best nucleic acid amplification and detection technologies for clinical molecular diagnostics - COVID-19 (FDA EUA Approved), Non Invasive Prenatal Test, HPV Detection, STI, NGS Cancer Panel (Lung, Breast, Colorectal), and many more.

AutoGenomics is a biotechnology company that offers an automated microarray based multiplexing molecular diagnostic platform to assess disease signatures with novel genetic biomarkers in the areas of women’s health, cancer and personalized medicine.

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. Our mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. We offer OGM solutions for applications across basic, translational and clinical research. Bionano also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through our Bionano Laboratories business, wey also offer OGM-based diagnostic testing services.

Bionexus offers a comprehensive line of biomedical products and services for the scientific community.

BioSpyder Technologies has developed a novel product for targeted sequencing called TempO-Seq™, a gene expression profiling tool designed to monitor hundreds to thousands of genes at once in high throughput. TempO-Seq can analyze expression in samples with thousands of cells or from single cells without pre-amplification, maximizing utilization of precious or limited samples. Sample barcoding, together with sequencing short fragments of each gene, enables pooling up to 6,144 samples in one sequencing run. Assay content is flexible and customizable delivering unprecedented accuracy and sensitivity.with simplified data analysis that eliminates the need for bioinformatics. TempO-Seq assays deliver an easy to use solution for customers doing expression profiling for any species.

Blueprint Genetics is a genetic diagnostics company focused on inherited diseases. We provide world-class genetic diagnostics and clinical interpretation for hereditary diseases. We are passionate about changing peoples’ lives through development of groundbreaking solutions that take genetic diagnostics from niche to mainstream. Our global team of innovative and motivated people are working at the forefront of genetic knowledge, AI and other areas of life science. Our team consists of more than 20 nationalities working as geneticists, data analysts, laboratory technicians, client service specialists, genetic services consultants, software developers and marketing specialists. Today, we work with customers in over 70 countries and push to make genetic knowledge easier to access for the medical community. Our comprehensive and cost-effective genetic tests support healthcare professionals around the world in providing the best care for patients and families with rare inherited diseases.

Bruker Spatial Genomics, Inc, (formerly Acuity Spatial Genomics, Inc.) provides a groundbreaking platform for simultaneous, genome-wide visualization of the 3D genome in single cells and opens new frontiers in spatial multiomic analyses for discovery. Based on patented technologies developed at Harvard University, the company’s jebFISH™ technology empowers researchers to directly visualize genome organization and 3D chromatin architecture of individual cells, directly in situ. The company’s transformative PaintScape™ platform, powered by jebFISH technology, breaks through challenges of multiplexed, direct imaging of the genome in nuclei and makes it possible to gain critical insight into cell programming and transcription regulatory programs that drive cell type, state, and function. Directly seeing changes and disruptions of genome organization will elucidate mechanisms of disease and its progression especially in disease systems like cancer. Bruker Spatial Genomics, Inc. is part of Bruker’s strategic investment in spatial biology and its initiative to develop and expand emerging spatial analyses technologies. The PaintScape platform joins the portfolio of high-performance Bruker Spatial Biology platforms that empower researchers to delve deeper and advance discovery in life science and translational research.

Cantata Bio is enabling researchers and clinicians to solve tomorrow’s most challenging scientific problems through novel, multiomic approaches that unlock access to genomic and metagenomic information at unprecedented levels. Combining propriety technologies with platform solutions, services, and cutting-edge bioinformatics and software, our unique approaches are solving complex problems, including chromatin topology analysis, small and large structural variant detection, de novo chromosome assembly, haplotype phasing, metagenomics, and microbiome analysis. Our customers are positively impacting the fields of epigenetics, developmental biology, cancer research, evolutionary biology, infectious disease, and more. Cantata Bio is based in Scotts Valley, California and Cambridge, Massachusetts. For more information on Cantata Bio, its technology, and offerings, visit www.cantatabio.com.

Celemics is a Next Generation Sequencing (NGS) full solution provider based on target enrichment technology. We confidently offer custom target enrichment panels and high-quality pre-set panels, covering fields such as Inherited Diseases, Oncology, Immunology, and Pathogen Diagnostics. With 13 years of experience, we will provide the best solution for your Targeted Sequencing. [Products/Services] OncoRisk (Hereditary Cancer) | CancerScreen (Somatic Cancer) | Custom Target Enrichment Panel | Whole Exome Sequencing | Clinical Exome Sequencing | BRCA 1/2 | PharmacoScreen | Comprehensive Respiratory Virus | Agrigenomics

Cellecta provides HT loss-of-function genetic screening services for the discovery and functional characterization of novel therapeutic targets. We offer pooled lentiviral shRNA and CRISPR libraries, pooled library screening and analysis by NGS, targeted RNA-Seq for biomarker discovery, lentiviral reagents, and stable cDNA, shRNA, and CRISPR constructs and isogenic cell lines.

We are an early-stage biotech startup based in Santa Cruz. We are a small, motivated, multi-disciplinary team innovating in NGS sequencing technologies and DNA assay design for applications in molecular diagnostics with focus on liquid biopsies, FFPE and ancient DNA Interested in beta testing our single-stranded approach to NGS library prep? Get in touch! www.claretbio.com/contact We are always looking to build our team with seasoned scientists who want to be on the ground-level of ground-breaking technology.

Invitae, now part of Labcorp, is a leading medical genetics company trusted by millions of patients and their providers to deliver timely genetic information using digital technology. We're working to provide accurate and actionable answers to strengthen medical decision-making for individuals and their families. Invitae's genetics experts apply a rigorous approach to data and research, serving as the foundation of our mission to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Within each of us lies information coded in our DNA that can transform our health. Unlocking that potential requires highly specialized, multidisciplinary collaboration. Our world-class genetics experts drive the development of a highly complex system of tools and processes, including robotics, artificial intelligence, machine learning, and software engineering. All of this comes together to provide patients with accurate, reliable results that can help guide decisions across the healthcare journey and potentially change lives today and for the next generation. Our teammates are grounded in a universal sense of urgency and ownership. We believe in the team above the individual and celebrate freedom with accountability. Employees are encouraged to speak up, try new things and make decisions that push us forward. We provide all Invitaens with opportunities to grow and advance, supported by flexible work hours, unlimited paid time off, the ability to work anywhere for many roles and the satisfaction of doing meaningful work. At Invitae, we're putting patients' genetic insights where they belong—at the center of healthcare. And we're doing it together, with you. Join us.

Clear Labs harnesses the power of next-generation sequencing (NGS) to simplify complex diagnostics for clinical and applied markets. By creating a fully automated platform that brings together DNA sequencing, robotics and cloud-based analytics, Clear Labs democratizes genomics applications to deliver increased clarity. Clear Labs’ turnkey platform accelerates outcomes and improves accuracy - from food-borne pathogens to infectious diseases, including SARS CoV-2. With a novel approach, Clear Labs is helping the world better understand, track and mitigate tomorrow’s novel pathogens.

Genetic testing, direct to consumerCOVID-19: EUA (05/2020) for their LAMP (Loop-mediated amplification) and uses three SARS-CoV-2-specific primer sets targeting the SARS-CoV-2 nucleocapsid gene (N), the envelope gene (E), and the ORF1a region.

Working on turning stem cells into human eggs

CureMatch is a leader in AI-based precision medicine, digital decision support solutions that support cancer treatment. Created to empower oncologists with world-class research and sophisticated AI algorithms, the CureMatch Decision Support System assists the doctor with understanding therapeutic options that are personalized to the unique molecular profile of the individual patient's tumor.

Developing simple to use technology to understand complex cellular biology. We are a team of scientists passionate about genomic technologies and how innovative technologies fuel new waves of scientific discoveries and clinical applications. Our group consists of reputable inventors in both academia and industry, as well as seasoned biotech entrepreneurs and executives with a strong track record in bringing genomic technologies from concept to commercialization.

We are a well-funded stealth biotech company backed by some of the most experienced operators and investors in the biotech industry. Our co-founders are highly experienced researchers, clinicians, and entrepreneurs, on a mission to improve precision medicine with cutting-edge genomic technology.

We are the first gut microbiome, genetics-based virtual care platform for people struggling with polychronic mental & physical illness associated with weight and gut. We use AI to harness clinical, genetic, gut microbiome, food and behavioral signals to target the root cause of illness. We deliver tailored whole-person care, including remote monitoring, food-as-medicine, pharma reduction, behavioral coaching support, and care coordination. We use AI to harness food information, clinical, genetic, gut microbiome, and behavioral signals, to deliver tailored holistic care, including food as medicine, behavioral coaching support, remote monitoring, and care coordination, to target the root cause of illness. Our customers love us because we acknowledge their unique physiology, lifestyle, food habits and deliver data-driven personalized care supported by specialist coaches that puts the customer in charge.

DNA COMPASS is implementing ‘last mile' bioinformatic solutions which bridge the gap between centers of genomic discovery and community health practices. Bringing to market data analytics and collaboration solutions which support healthcare professionals by extending the reach of data-driven medicine into community practices. WHY: At DNA Compass, we believe linked health data must work harder, faster, and for more patients. It must empower clinicians NOW to accelerate accurate diagnoses, increase treatment success, and deliver better outcomes. BREAST CANCER DEMO http://dnabreast.com

DNA Link Sequencing Lab is a business unit with DNA Link, Inc, which is dedicated to providing DNA sequencing services to researchers worldwide. Founded in 2000, it has extensive experience in all genomics tools, and our fleet of sequencers include PacBio Sequel, RSII, HiSeq and NextSeq as well as Affymetrix array platforms.

Develop artificial intelligence that is utilized to aid and augment certified genetic counselors and pharmacists, during pre-test, post-test and support services.

Dovetail Genomics is reimagining the life sciences by unlocking access to genomic structure at an unparalleled level. Through Dovetail Genomics' proprietary proximity ligation technologies, the 3-D architecture of the genome is captured alongside primary sequence information using standard next-generation sequencing (NGS) approaches. Researchers are using Dovetail Genomics' unique methods to solve complex problems including chromatin topology analysis, small and large structural variant detection, de novo chromosome assembly, haplotype phasing and microbiome analysis in the fields of epigenetics, developmental biology, cancer research, evolutionary biology and more. Through our services and assay kit offerings, Dovetail Genomics is ready to partner with you to elevate your genome research to a new level. Researchers are using Dovetail Genomics' unique methods to solve complex problems including chromatin topology analysis, small and large structural variant detection, de novo chromosome assembly, and haplotype phasing in the fields of epigenetics, developmental biology, cancer research, evolutionary biology and more. Through our services and assay kit offerings, Dovetail Genomics is ready to partner with you to elevate your genome research to a new level.

DxTerity is bringing the power of precision medicine to autoimmune disease. We are pioneering the use of RNA-based immune system profiling to better understand the root causes of immune mediated conditions. Our goal is to provide more personalized care for autoimmune sufferers and empower patients with more detailed information about their condition so they can better navigate their complex health journey.

We are now at the dawn of the synthetic biology revolution, which will spawn new applications, markets, and business models, improving human lives in countless ways. This revolution will be driven by new technologies that enable DNA writing at speed and scale. To catalyze this revolution, Elegen is creating a suite of ground-breaking technologies to achieve DNA writing with unparalleled speed, cost, and quality. Elegen is unlocking the power to reprogram biology and create biologic solutions in order to solve some of humanity's greatest challenges. Founded and led by Dr. Matthew Hill and located in San Carlos, CA, Elegen is a stealth-mode company that is well capitalized by top life science investors, including Andreessen Horowitz, 8VC, and KdT. The company is advised and staffed by leading biotechnology scientists and entrepreneurs, including Dr. Marc Unger, inventor of the Nanoflex™ valve and former CSO of Fluidigm. Dr. Hill has a PhD from Stanford and a proven track record of advancing innovative technologies from invention to commercial success.

Element Biosciences is a multi-disciplinary startup focused on developinggenetic analysis tools for the research and diagnostic markets.

Engine Biosciences is a venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine. Our proprietary and patented technologies oriented around deciphering the complexity of biology networks include both high-throughput wet lab experimentation and artificial intelligence algorithms for drug discovery and cellular reprogramming. This platform, developed through several years of research by our scientific founding and leadership team who include faculty members at MIT, Harvard, Mayo Clinic, and UCSD, dramatically accelerates and reduces costs of the R&D process for new medical therapies. We are actively applying the platform internally and with partners across a range of disease indications. In January 2018, we announced the closing of a US$10M seed round from notable biotech and tech institutional investors and are expanding the team.

Exceltox is a CAP-accredited, CLIA-certified laboratory offering advanced clinical, pharmacogenomic,and toxicology testing.

Fauna Bio is inspired by the untapped potential of non-model organism biology. We leverage insights from extraordinary mammalian phenotypes to develop novel translational therapeutics for disease prevention and reduce the impact of age-related diseases in humans.

Fore Genomics, a clinically-focused genetics company, has launched FORESITE 360, a leading-edge product offering clinical-grade, in-depth sequencing for the littlest patients. Focusing on newborns and children, a simple cheek swab sample provides doctors and parents with valuable genetic insight into a child's potential for future diseases based on their DNA. Backed by the reliability of CLIA-certified and CAP-approved labs, FORESITE 360 is designed to offer a complete genetic profile of your child, unlocking a lifetime of health insights. FORESITE 360 incorporates ongoing re-analysis of DNA, allowing doctors to take practical steps toward managing any detected medical conditions. Without adding a single item to their to-do list, clinicians can now add value for their patients with leading-edge sequencing, high-quality genetic counseling, and annually updated analysis.

Our mission is to develop flexible and affordable diagnostics and therapeutics that improve the everyday lives of those around us. Founded in 2011, Fulgent has evolved into a premier, full-service genomic testing company built around a foundational technology platform. Through our diverse testing menu, Fulgent is focused on transforming patient care in oncology, anatomic pathology, infectious and rare diseases, and reproductive health. We believe that by providing a wide range of effective, flexible testing options in conjunction with best-in-class service and support, we can redefine the way medicine is managed for patients and clinicians alike. - Our Products & Services - Fulgent Genetics https://www.fulgentgenetics.com/ Fulgent Oncology https://fulgentoncology.com/ Fulgent BioPharma https://biopharma.fulgent.com/ Picture Genetics https://picturegenetics.com/ HelioLiver https://www.helioliver.com/ Fulgent is a CLIA-certified and CAP-accredited laboratory. _____________ NASDAQ: FLGT

Function Oncology is a precision medicine company advancing a CRISPR-powered personalized functional genomics platform to understand cancer in unprecedented and patient-specific detail. By moving beyond traditional gene sequencing to measuring gene function, Function Oncology aims to identify optimal therapeutic opportunities for patients and advance the next generation of targeted cancer therapies.

State-of-the-art diagnostic laboratory providing comprehensive pathology, DNA Sequencing, pharmacogenetic and toxicology testing solutions.

Enabling users to establish #ownership & #control over their Biosamples & derived datasets as Non-fungible Tokens. We call them #BioNFTs 🧬.

Process, analyze, and annotate genomics and biomedical data at scale using containerized workflows.

Hexagon Bio is a biopharmaceutical company pioneering the discovering novel payloads for antibody-drug conjugates (ADCs) to address critical unmet needs in oncology. Leveraging a proprietary platform, the company mines cytotoxic small molecules from microbial genomes for use as ADC payloads. Advances in DNA sequencing have enabled the identification of both existing ADC payloads—such as topoisomerase and tubulin inhibitors—and novel payload mechanisms targeting essential cancer pathways such as protein translation. Hexagon Bio is advancing a pipeline of next-generation ADC candidates with novel payloads designed to treat a wide range of solid tumors and hematological malignancies.

At Illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

INanoBio’s mission is to develop high-accuracy early stage disease diagnostics using transformative nano-biotechnology platforms and machine learning. Extract systems scale information from complex disease biology, identify and detect disease specific molecular biomarkers, signatures at prodromal or pre-symptomatic stages. We believe most diseases can be detected early, enabling early personalized therapeutic intervention to preempt full development of diseases, ushering in preemptive medicine.

Inocras is a company for whole genome sequencing, providing a comprehensive view of a patient's entire genetic profile through WGS analysis and interpretation. Focusing on cancer and rare diseases, we aspire to fundamentally change how the world treats genetically driven diseases with an unsurpassed WGS databank and an integrated platform for generating, collecting, and analyzing genomic data.

Inscripta® is a life science technology company committed to creating a cleaner, healthier, and more sustainable world through biomanufacturing. A global leader in genome engineering, our innovations are designed to unlock the full potential of the bioeconomy. We are committed to the continued development of critical technologies that enable scientists to bolster and expand domestic biomanufacturing, and spur new, safe, and secure biotech innovations. Inscripta supports customers around the world from facilities in Pleasanton and Burlingame, California. To learn more, visit Inscripta.com and follow @InscriptaInc.

Intelliseq provides state of the art solutions for next generation sequencing. A team of passionate and skilled bioinformaticians, geneticists and molecular biologists approaches next generation DNA sequencing challenges with creativity and flexibility.

Jumpcode Genomics is changing the way scientists see their samples with our proprietary CRISPRclean® technology. Combining CRISPR-based technology and next-generation sequencing (NGS) they can now search for and find novel signals they previously couldn't. Our technology removes unwanted sequences, allowing researchers worldwide to extract greater insights. By increasing sensitivity and allowing access to a range of sample types, we're broadening the understanding of human biology in fields from research to clinical applications including infectious disease and oncology.

Lab Genomics, LLC (LG) is focused on delivering individualized medical care through molecular and genetic diagnostics.

MEDIC Life Sciences is a biotechnology company that specializes in resurrecting cancer drugs from failed clinical trials using proprietary technology to produce 2 million different tumor samples for testing.

Mission Bio is a company of passionate people dedicated to solving complex biological problems with precision engineering, innovative biochemistry, and supported bioinformatics. In 2014, the company was spun out of Adam Abate’s lab for high-throughput biology at the University of California, San Francisco (UCSF). Mission Bio’s precision genomics platform is based on the pioneering droplet microfluidics work of Abate and his team. Our mission is to help researchers and clinicians unlock single-cell biology to enable the discovery, development, and delivery of precision medicine. Visit missionbio.com to learn more.

Molecular Assemblies, Inc. is a private life sciences company developing an enzymatic DNA synthesis technology designed to power the next generation of DNA-based products. The company's patented Fully Enzymatic Synthesis (or FES™), based on making DNA the way nature makes DNA, produces long, high quality, sequence-specific DNA reliably, affordably, and sustainably. FES technology will enable the reading and writing of DNA for many industries, including industrial synthetic biology and precision medicine, as well as emerging applications of nanomachines and bio-based electronics. Molecular Assemblies is headquartered in San Diego. *Fully Enzymatic Synthesis and FES are the trademarks of Molecular Assemblies, Inc.

NantOmics employs a comprehensive, integrated panomic approach to detect molecular alterations in individual tumors and inform personalized treatment options for patients with cancer. Whole genome sequencing of a patient’s matched tumor sample and normal sample pinpoints tumor-specific alterations at the DNA level, RNA sequencing confirms and gives relevance to mutations in DNA, quantitative proteomics measures the levels of clinically important proteins, and integrative analysis identifies disrupted pathways that are specific to the patient’s tumor.

Natera™ is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women's health, and organ health. Our aim is to make personalized genetic testing and diagnostics part of the standard of care to protect health and enable earlier and more targeted interventions that lead to longer, healthier lives. Where some set out to build a test, we set out to achieve a mission: change the management of disease worldwide by using DNA testing to proactively inform treatment.  Through a cfDNA technology platform approach, we've pioneered noninvasive testing in unlimited applications—each with their own potential to revolutionize care for patients. #TeamNatera includes clinicians, scientists, biostatisticians, researchers, and laboratory professionals from around the world. Our diverse teams blend a passion for patients with deep clinical, scientific, and technological roots. Natera's tests are validated by more than 100 peer-reviewed publications that demonstrate high accuracy. Interested in joining us on our mission to change the management of disease worldwide? Visit https://www.natera.com/careers-at-natera to learn how you can become a part of our talented team. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. Please be advised that Natera will reach out to candidates with an @natera.com email domain ONLY. Email communications from all other domain names are not from Natera or its employees and are fraudulent. Natera does not request interviews via text messages and does not ask for personal information until a candidate has engaged with the company and has spoken to a recruiter and the hiring team. Natera takes cyber crimes seriously, and will collaborate with law enforcement authorities to prosecute any related cyber crimes. https://www.natera.com/privacy/

Born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, Nautilus (Nasdaq: NAUT) set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. The extraordinary team at Nautilus represents a wide spectrum of disciplines and expertise, including: protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. Nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.

NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Advanced Diagnostics Division serves pharmaceutical clients in clinical trials and drug development. NeoGenomics is committed to connecting patients with life altering therapies and trials. We believe that, together, with our partners, we can help patients with cancer today and the next person diagnosed tomorrow. In carrying out these commitments, NeoGenomics adheres to relevant data protection laws, provides transparency and choice to patients regarding the handling and use of their data through our Notice of Privacy Practices, and has invested in leading technologies to secure the data we maintain. Headquartered in Fort Myers, FL, NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida; Aliso Viejo and San Diego, California; Research Triangle Park, North Carolina; and Houston, Texas; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom. NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and a pharmaceutical firm in Europe.

NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.

Newomics is a biotech company that sells and develops innovative and integrative platforms for LC-MS. In particular, the award-winning multinozzle M3 emitter, with the MnESI ion source, enhances the ionization efficiency to achieve unprecedented sensitivity, throughput, and robustness. Our proprietary technology is based on silicon-microfluidic-chip for liquid chromatography-mass spectrometry (LC-MS), and offers unprecedented robustness, sensitivity, specificity, and throughput for analyzing molecules from minute amounts of biospecimens such as blood and urine. Our core technologies are built upon the multinozzle emitter array (MEA) technology, invented from the Lawrence Berkeley National Laboratory (Berkeley Lab), which has won the 2012 R&D 100 award.

NinthBio is a software company serving Biotech. Our flagship product is "Homology Path", an application that designs the oligos for DNA synthesis. The value is how few oligos are needed to build a a group of similar DNA sequences. Think of the DNA you would need to test for a protein engineering campaign, or to optimize the affinity of an antibody. All require similar but ultimately unique DNA. Our customers can improve their Design, Build, Test Learn Cycle by 15X all while decreasing their DNA spend 10 fold. Researchers are rethinking where and what they are willing to explore given the power of Homology Path, opening the door for rapid and higher value discovery. Want to see how this can help your initiatives; request a demo token to access the capabilities of Homology Path.

OnsiteGene Inc. is a biomedical technology company developing on-site genetic testing based on a new sample prep and qPCR process.

At PacBio, we’re devoted to empowering you. Pioneering the future through biology takes vision. You have to look beyond the status quo to what’s possible. We know your vision can reveal the full potential of the genome, advance human health and the health of our planet. And that is why your vision and pursuit are at the very center of what our company does — our product design, our customer support model, our partnerships, and even our identity. We create the world’s most advanced sequencing systems to provide you the most complete and accurate view of genomes, transcriptomes, and epigenomes. Our founders invented a new way to study the synthesis and regulation of DNA, RNA, and proteins. Driven by a desire to advance human health, we’re harnessing advances in biochemistry, optics, nanofabrication, and more. We are passionate about developing products that empower scientists to explore the full spectrum of genetic variation in any organism — from unraveling the mystery of rare diseases to improving the world’s food supply. With world-class service and support, we keep your research progressing so you can focus on finding answers. We encourage you to see the whole picture — and consider us the partner you trust to see it too.

Phalanx Biotech Group provides genomics research products and services worldwide to academic, pharmaceutical and biotech communities. We developed the OneArray® line of high-quality and affordable microarrays for expression profiling of whole genomes, microRNA, and custom targets. Our service specialists offer comprehensive services including sample preparation, expression analysis, and qPCR validation. In 2017, Phalanx is pleased to announce that it has added Next Generation Sequencing Services (NGS) and corresponding NGS Bioinformatics to its service offerings.

Disrupting research enzyme/protein production, we are the first to introduce a Taq Polymerase free from background DNA contamination. We are now proud to introduce our new RNA extraction free EF1 SARS-CoV-2 Detection Kit, CE marked for in vitro diagnostics! Find out how we plan to have the gold standard of testing available with results in less time it takes to explain your job to grandma!

Predictive Biologybrings together stem cell biology, high throughput screening and genetics to elucidate molecular mechanisms underlying compound response.

At Primex Clinical Laboratories, we're dedicated to enhancing health with precision and passion. Since 1996, our presence in clinical diagnostics has been unwavering, serving diverse clients across Central and Southern California, Nevada, and American Samoa. We're more than a testing facility, our laboratory is a center of innovation and reliability. We pride ourselves on delivering personalized customer service, and high-quality testing with quick and accurate results, contributing to our community's health and well-being. Understanding the vital role of diagnostics in healthcare, we aim to be your most trusted lab partner. Our focus extends beyond recognition; we strive to gain your trust through personalized service, precise testing, and innovative solutions. We dedicate ourselves daily to advancing healthcare with meticulous care and a personal touch, shaping a healthier future. Learn more at Primexlab.com.

PrognomiQ aims to generate proteomic information with high accuracy, scale and speed. This proteomic data will be complemented with genomic, metabolomic and other health information to deliver first-in-class test products that enable early disease detection and treatment. Powerful, Untapped Disease Insights Built on a Proteomics Foundation: Until now, there have been major technical and economic barriers to broad-scale proteomics analyses, leaving this rich resource of molecular information largely untapped for clinical purposes. These barriers have now been largely addressed through next generation tools that can elucidate complex proteomics at scale. Complementary Molecular Information: Genomic data has made clear contributions to researchers' abilities to understand and more precisely treat disease, but it is has shown limited impact on early-stage disease detection. Proteomics provides direct information on the biological state of a cell, including disease at its earliest state, but proteomics data has been technically difficult to generate – until now. By complementing the new sources of proteomics data with genomics and other data, such as metabolomics, we now have the tools to generate powerful multi-omics data that will be the key to unlock the detection and treatment of disease at its earliest stages, when these diseases are most likely to be cured. Unlocking Disease Detection and Treatment with Multi-omics Data: We designed our proprietary multi-omics platform around the most robust approaches to generating proteomic, genomic and metabolomics data at scale, including the use of the Proteograph technology platform from the life science tools company Seer (NASDAQ: SEER) whom PrognomiQ spun out of in 2020.

Protillion Biosciences is a Stanford University spinout commercializing disruptive technology for therapeutic antibody and binder discovery. We have developed an entirely novel, powerful and high-throughput protein display platform designed to revolutionize traditional approaches to the design and development of protein-based drugs.

QBench is a cloud-based Laboratory Information Management System (LIMS) that enables labs to streamline their entire testing workflow, from sample receiving to automated results reporting. We're the modern, configurable, easy-to-use solution that allows our customers to get a LIMS up and running faster. QBench eliminates the need to have spreadsheets, shared network folders, and paper­-based tracking systems. Automate your entire lab with our developer-friendly API, Inventory Management, Customer Portal, Billing, and Quality Management System modules. Contact us by email at sales@qbench.com or phone at (888) 680-5834 to request a demo of our software!

Ravata Solutions is a fertility and reproduction company that specializes in hardware and diagnostics to transform the IVF laboratory with automated assisted reproductive technologies (AART) and enhance human disease model development for pre-clinical studies.

RealSeq Biosciences’ core expertise includes innovative proprietary technologies for bias-free small RNA/miRNA NGS library construction, targeted NGS tools, and cf-RNA analysis (liquid biopsy) that form the basis of the Company’s life science research programs and product development.

Real Time Genomics develops analytical solutions that reduce the cost and complexity of extracting knowledge from raw genomic data. We deliver validated, accurate results that are redefining personalized medicine. ___________________________________________________________________________________ At Real Time Genomics, we have a passion for genomics. Our core competence is a commitment to know, anticipate and deliver to the needs of leading biological researchers. The company has deep computational expertise in algorithms, coupled with extensive product development capabilities and a seasoned commercial team with over 100 years of success in bringing genomics' innovation to the life sciences industry. Today,we offer solutions for genomic analysis to practitioners of next generation sequencing (NGS) technologies. These solutions include complete analytical platforms for genomics and metagenomics. We can install these platforms to your compute environment or provide you access to them through cloud computing.

RyboDyn, Inc. is targeting the dark proteome to make new immunotherapies. We are unlocking and validating previously undiscovered, disease-specific targets that will impact the treatment of cancer and autoimmune diseases by driving a new wave of targeted therapeutics. Our "targets-to-assets" therapeutics development program is supported by a scalable, in-house platform for lead discovery and optimization. We aim to deliver first-in-class assets that recognize these targets for treating solid tumors and diseases lacking effective treatment options.

S2 Genomics is developing integrated sample preparation systems processing tissues and liquid samples into genomic samples.S2 Genomics is also developing single cell spatial sequencing™technology that will capture the spatial location,i.e., 3-dimensional coordinates, of single cells in tissue for NGS readout.

Salimetrics supports thousands of salivary researchers in more than 20 countries around the world. Our assays have been used in more saliva-related published papers than any other assay in the field. We believe Salimetrics is a unique company. We combine uncompromising scientific process with human passion to deliver what we hope are superior products and services for saliva testing and collection. We provide consultation, assistance with study design, advice for funding, and support for all things saliva testing-related, because we believe saliva testing can help researchers learn and discover things that will translate to cures, treatments and understanding around the world. If you have a ground-breaking study, ideas for innovative saliva testing products, or simply need advice, please don't hesitate to contact us. We work with a diverse network of saliva researchers around the world. This network extends the salivary research community by providing credible, data driven results that advance the scientific field of salivary research. Together, we can make a difference. To place an order, request a quote, or have your questions answered please visit our website. https://salimetrics.com/contact/ We are always ready to assist you!

SciGene manufactures and sells instruments, equipment and reagents for chromosome and FISH slide processing in cytogenetics laboratories.

Revolutionizing the healthcare industry by providing an integrated AI platform that provides personalized health recommendations based on a combination of your DNA, labs, and environmental factors. SelfDecode is the only company in the world providing ancestry-adjusted Polygenic Risk Scoring directly to the consumer. Through our R&D division (OmicsEdge), we are making precision health affordable to all by empowering organizations to easily build precision health products using our bioinformatics infrastructure. Our core abilities include ancestry-adjusted Polygenic Risk Scoring, which we license to other organizations.

Our mission is to create a new generation of smarter medicines that outmaneuver complex diseases in ways previously inconceivable. To accomplish this mission, we are building a synthetic biology platform that could enable us to program next-generation cell and gene therapies with what we refer to as “gene circuits”. These gene circuits, which are created from novel and proprietary combinations of DNA sequences, are intended to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. We are designing gene circuits to improve the “intelligence” of cell and gene therapies in order to enhance their therapeutic effectiveness against a broad range of diseases that conventional medicines do not readily address. For more information, please visit the Senti Bio website at https://www.sentibio.com.

We are excited to continue to support women's health under the Labcorp name. Follow us @Labcorp

Singular Genomics is driving innovation at the forefront of multiomics. Dedicated to supporting the scientific community, we focus on creating scientific advancements influenced by real-world feedback and solution-oriented development. As a publicly-traded life science technology company, we specialize in advanced next-generation sequencing (NGS) and multiomic technologies, developing products that empower researchers and clinicians. The G4 Sequencing Platform, our first commercially available product, is an innovative benchtop sequencer featuring a novel 4-color rapid sequencing-by-synthesis (SBS) chemistry and advanced engineering, providing single-day turnaround times for various applications. Our recently launched G4X Spatial Sequencer, which is an upgrade to the G4 Sequencing Platform, is designed to offer high throughput in situ direct sequencing of RNA (Direct-Seq™), targeted transcriptomics, and proteomics profiling from formalin-fixed, paraffin-embedded (FFPE) tissues. We are committed to unlocking the potential of our core technologies to reshape the future of multiomics. We offer a dynamic, fast-paced, results-oriented environment where employees can make a significant impact. Innovation, continuous learning, multi-disciplinary collaboration, and diversity of thought are pillars of our culture.

info@smlgenetree.com | www.smlgenetree.com | SML Genetree is recognized as a premier partner in developing technology and on-time delivery, providing both basic research of molecular biology and applied research in molecular diagnosis. SML Genetree is an affiliate of Samkwang Medical Laboratories (SML), one of the largest diagnostic commercial labs in South Korea in 1985.

Takara Bio USA, Inc. (formerly Clontech Laboratories, Inc.), a Takara Bio company, develops, manufactures, and distributes a wide range of life science reagents under the Takara®, Cellartis®, and Clontech® brands. Our products support applications including stem cell research; NGS; gene discovery, regulation, and function studies; protein expression and purification; RNAi and gene editing; and plant and food research.

Twist Bioscience is a synthetic biology company based in South San Francisco, California. The company has developed a proprietary silicon-based manufacturing process for the production of synthetic DNA. Twist Bioscience serves Life Science researchers who are changing the world for the better. Coming from diverse fields of medicine, agriculture, industrial chemicals and data storage, scientists use our synthetic genes, oligo pools, and NGS target enrichment to better lives and improve the sustainability of the planet. Twist Bioscience is uniquely positioned to help accelerate these efforts by providing precision at a scale that is otherwise unavailable. Our technology overcomes inefficiencies and enables cost-effective, rapid, precise, high-throughput DNA synthesis and sequencing. We offer both the quality and quantity researchers need now to rapidly realize opportunities ahead. Twitter @TwistBioscience Facebook facebook.com/TwistBioscience YouTube youtube.com/TwistBioscience #WeMakeDNA

Vivid Genomics enables pharma companies to select and stratify the right patients for their clinical trials, increasing the probability of trial success and getting to an approved drug. We use machine learning and genomics to develop blood-based, genetic tests (“Genomic BiopsyTM”) for neurodegenerative diseases, beginning with Alzheimer’s.